A reduced dose of soybean fat emulsion seems to be better than the standard dose at preventing parenteral nutrition-associated…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
BILIARY ATRESIA
NewsTriple blood test may be best at diagnosing biliary atresia
The blood levels of two proteins, called MMP-7 and SOX9, are significantly higher in infants with biliary atresia than…
ALAGILLE SYNDROME
NewsWorld Liver Day to raise awareness of Alagille, other liver diseases
April 19 is a day set aside to raise awareness of liver diseases such as Alagille syndrome. It’s…
Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population…
Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with…
BILIARY ATRESIA
NewsBlood protein predicts post-transplant liver fibrosis in biliary atresia
A blood test that measures the levels of the M2BPGi protein accurately predicts the presence of moderate liver scarring, or…
Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary…
Having gestational diabetes increases the risk of adverse outcomes in pregnancy for women with intrahepatic cholestasis of pregnancy (ICP),…
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily…
FATTY LIVER DISEASE
NewsSmall amounts of alcohol deemed OK in early steatotic liver disease
Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages…